Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1995 1
1996 1
1997 2
1998 1
2000 2
2001 1
2003 1
2004 1
2005 1
2006 3
2007 4
2008 5
2009 2
2010 6
2011 3
2012 6
2013 5
2014 6
2015 3
2016 1
2017 3
2018 5
2019 4
2020 1
2021 3
2022 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ. Neogi T, et al. Among authors: sundy js. Ann Rheum Dis. 2015 Oct;74(10):1789-98. doi: 10.1136/annrheumdis-2015-208237. Ann Rheum Dis. 2015. PMID: 26359487 Free PMC article.
2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vazquez-Mellado J, Yarows SA, Taylor WJ. Neogi T, et al. Among authors: sundy js. Arthritis Rheumatol. 2015 Oct;67(10):2557-68. doi: 10.1002/art.39254. Arthritis Rheumatol. 2015. PMID: 26352873 Free PMC article.
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy JS, Jahreis A, Genovese MC, Mozaffarian N, Landewé RBM, Bae SC, Keystone EC, Nash P. Combe B, et al. Among authors: sundy js. Ann Rheum Dis. 2021 Jul;80(7):848-858. doi: 10.1136/annrheumdis-2020-219214. Epub 2021 Jan 27. Ann Rheum Dis. 2021. PMID: 33504485 Free PMC article. Clinical Trial.
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T. Genovese MC, et al. Among authors: sundy js. JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055. JAMA. 2019. PMID: 31334793 Free PMC article. Clinical Trial.
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA. Sundy JS, et al. JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169. JAMA. 2011. PMID: 21846852 Clinical Trial.
The rheumatology of gout.
Sundy JS. Sundy JS. Adv Chronic Kidney Dis. 2012 Nov;19(6):404-12. doi: 10.1053/j.ackd.2012.07.012. Adv Chronic Kidney Dis. 2012. PMID: 23089276 Review.
Update on nonsteriodal anti-inflammatory drugs.
Ardoin SP, Sundy JS. Ardoin SP, et al. Among authors: sundy js. Curr Opin Rheumatol. 2006 May;18(3):221-6. doi: 10.1097/01.bor.0000218940.04613.cc. Curr Opin Rheumatol. 2006. PMID: 16582683 Review.
Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.
Scheid JF, Cunningham-Bussel K, Kim N, Agarwal S, Nieddu G, Cote J, Lemoine L, Decaesteker T, Mendez L, Paul E, Love-Gregory L, Contreras AV, Zhao X, Franco-Dilone L, Pang L, Baltus GA, Beaumont M, Shah K, Higginson-Scott N, Kis-Toth K, Otipoby KL, Viney JL, Sicard E, Rottey S, Sundy JS, Van Dyck K, Laethem T, Larson P, Sutradhar S, Wnek R, Bueters T, Lai E, Stoch SA, Iwamoto M, Robbins JA. Scheid JF, et al. Among authors: sundy js. Immunohorizons. 2025 Mar 26;9(5):vlaf005. doi: 10.1093/immhor/vlaf005. Immunohorizons. 2025. PMID: 40139976 Free PMC article. Clinical Trial.
Refractory gout: what is it and what to do about it?
Fels E, Sundy JS. Fels E, et al. Among authors: sundy js. Curr Opin Rheumatol. 2008 Mar;20(2):198-202. doi: 10.1097/BOR.0b013e3282f4eff5. Curr Opin Rheumatol. 2008. PMID: 18349751 Review.
71 results